A study in The Lancet indicates that GLP-1 drugs such as Ozempic could significantly benefit kidney transplant patients by reducing the risk of organ failure by 49% and lowering the mortality rate by 31% within five years. However, the study also highlights a 49% increased risk of diabetic retinopathy among users, underscoring the need for careful monitoring of eye health.
Full Story: HealthDay News (3/6)